Navigation Links
Ranbaxy Gains Approval to Manufacture and Market Carvedilol Tablets in the U.S. Market
Date:9/6/2007

BLOCKBUSTER BRAND WILL BE COMMERCIALIZED AS AFFORDABLE GENERIC

PRINCETON, N.J., Sept. 6 /PRNewswire/ -- Ranbaxy Pharmaceuticals Inc. (RPI), a wholly owned subsidiary of Ranbaxy Laboratories Limited (RLL), announced today that RLL has received approval from the U.S. Food and Drug Administration to manufacture and market Carvedilol Tablets, 3.125 mg, 6.25 mg, 12.5, and 25 mg, a beta blocker used to treat heart failure. The Office of Generic Drugs, U.S. Food and Drug Administration, has determined the Ranbaxy formulations to be bioequivalent and have the same therapeutic effect as that of the reference listed drug Coreg(R) Tablets, 3.125 mg, 6.25 mg, 12.5 mg, and 25 mg, respectively, of GlaxoSmithKline. Total annual market sales for Carvedilol Tablets were $1.6 billion (IMS - MAT: June 2007).

Carvedilol is indicated for the treatment of mild-to-severe heart failure of ischemic or cardiomyopathic origin, usually in addition to diuretics, ACE inhibitor and digitalis. Carvedilol is also indicated to reduce cardiovascular mortality in clinically stable patients who have survived the acute phase of a myocardial infarction, as well as in the management of essential hypertension, alone or in combination with other antihypertensive agents.

"We are pleased to receive this FDA approval for Carvedilol Tablets that will add depth and breadth to our product line of medications used in cardiovascular diseases. This approval further represents yet another approval in 2007, that expands our product portfolio of affordable generic alternatives. Carvedilol will be manufactured at our Ohm Laboratories facility in New Brunswick, New Jersey and launched in to all classes of trade early in the fourth quarter of 2007 under the RPI label," noted Jim Meehan, Vice President of Sales and Distribution for RPI.

Ranbaxy Pharmaceuticals Inc. (RPI) based in Jacksonville, Florida, is a wholly owned subsidiary of Ranbaxy Laboratories Limited (RLL), India's largest pha
'/>"/>

SOURCE Ranbaxy Pharmaceuticals Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. RANBAXY - enters anti-AIDS segment
2. Ranbaxy joins hand with Cipla to co-market ciprofloxacin
3. Ranbaxy gets US FDA approval for Lisinopril
4. Ranbaxy Labs Entry Into Anti-Acne Market
5. Ranbaxy trying to make inroads in herbal drugs market
6. Lamivudine Manufactured By Ranbaxy gets the nod from the US FDA
7. Ranbaxy Pharmaceuticals Inc awarded the prestigious outstanding supplier award received from Wal-Mart
8. Ranbaxy opens Drug discovery centre in Gurgaon
9. Ranbaxy Laboratories All Set To Export Bird Flu Vaccines
10. Ranbaxy Gets USFDA Approval For Doxycycline Tablets
11. SRL Ranbaxy offers quicker bird flu diagnostic test
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/26/2014)... 2014 Cooking and warming equipment ... of 5. This score reflects slightly positive negotiation conditions ... specialization, low switching costs and a low level of ... low availability of substitutes for cooking and warming equipment ... and aluminum, key inputs in the production process of ...
(Date:12/26/2014)... (PRWEB) December 26, 2014 “Many people ... with personal injury claim issues and phone calls with ... released an article featuring their free eBook on ... helpful eBook on pedestrian and bicycle auto accident claims ... is fully capable of professionally handling their case while ...
(Date:12/26/2014)... AZ (PRWEB) December 26, 2014 ... source for the best in heating, cooling and ... for 24 hour emergency services in 2014 with ... alike know that Arizona is known for its ... company that understands the intricacies and details of ...
(Date:12/25/2014)... 26, 2014 The report “Nintedanib ... 2023” focuses on the current treatment landscape, unmet ... colorectal cancer market. Stivarga is a drug which ... rectal cancer. Boehringer Ingelheim is developing nintedanib (BIBF-1120), ... of refractory CRC in the US, Europe, and ...
(Date:12/25/2014)... Recently, iFitDress.com, the popular online supplier of ... its new selection of black one-shoulder cocktail dresses . ... they are available at discounted prices, up to 70% off. ... last for three weeks only. You know, we have thousands ... interested in our new items can visit our website for ...
Breaking Medicine News(10 mins):Health News:Cooking & Warming Equipment Procurement Category Market Research Report from IBISWorld has Been Updated 2Health News:Cooking & Warming Equipment Procurement Category Market Research Report from IBISWorld has Been Updated 3Health News:Guide to Handling Pedestrian and Bicycle Accidents Released By The Jones Firm, Featured in Recent Article 2Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 2Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 3Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 4Health News:iFitDress.com: Black One-Shoulder Cocktail Dresses for 2015 2
... Against the backdrop of last week,s Congressional hearing into ... at Buffalo,s Laboratory for Forensic Odontology Research in the ... on the controversial topic of bitemark analysis. The Congressional ... of Sciences (NAS) report on the scientific basis of ...
... Sept. 16 Managed Health Care Associates, Inc. (MHA), ... the country, today announced the immediate availability of RxPertise ... Regimen Review (MRR) software for consultant pharmacists in the ... efficiently manage the utilization, outcomes, and reporting requirements for ...
... abuse among undergrads, study shows , WEDNESDAY, Sept. 16 ... among university students, but an Internet-based intervention may help ... , Researchers analyzed data from a Web-based alcohol-use screening ... aged 17 to 24, in Australia, and found that ...
... The most important voice is YOURS! ... The Pennsylvania Breast Cancer Coalition (PBCC) Annual Conference will be held on ... 8:30 a.m. to 3:30 p.m. , , ... Pennsylvania Breast Cancer Coalition Annual Conference is the only statewide breast cancer ...
... , , , ... California hospital industry, El Camino Hospital CEO, Ken Graham, will provide insight ... Healthcare CEO Summit on Sept. 17 at 7:15 a.m. at the Rotary ... leadership, Graham has much to contribute to the health care reform debate. ...
... www.intelligenthospitals.com , , WINNIPEG, Sept. 16 ... pharmacy across North America, 77% of those looking to ... Intravenous Automation) - a self-contained unit for filling IV ... - as a vendor under consideration. The survey was ...
Cached Medicine News:Health News:Bitemark evidence and analysis should be approached with caution, according to UB study 2Health News:Bitemark evidence and analysis should be approached with caution, according to UB study 3Health News:MHA Announces Release of RxPertise(TM) 8.0 2Health News:Internet Can Help Curb Drinking Among College Students 2Health News:Pennsylvania Breast Cancer Coalition Hosts Annual Conference 2Health News:El Camino Hospital Provides Local Perspective on Health Care Reform and Innovation at Silicon Valley Healthcare CEO Summit 2Health News:IH Systems RIVA Top Pick for Directors of Pharmacy 2
(Date:12/24/2014)... -- ResMed (NYSE: RMD ) today announced its ... device manufacturer BMC Medical Co., Ltd. The ... below infringe ResMed,s patents, and entered an order prohibiting BMC ... the United States : , iVolve nasal ... nasal pillows mask , iVolve full face mask ...
(Date:12/24/2014)... , Dec. 23, 2014   Assurex Health, ... support to healthcare providers for behavioral health and ... secured $30 million in equity financing from new ... Drosos , President and Chief Executive Officer. ... and development of Assurex Health,s GeneSight ® ...
(Date:12/24/2014)... China , Dec. 23, 2014 ... pharmaceutical company that specializes in patented biopharmaceutical, modernized ... pharmaceutical ingredients (API) today announced that the Company ... its Good Manufacturing Practice (GMP) certificate of TPI,s ... Drug Administration,s (CFDA). The public notice period is ...
Breaking Medicine Technology:ResMed Wins Patent Infringement Lawsuit Against Chinese Manufacturer BMC Medical 2Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 2Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 3Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 4TPI QLF Achieved Public Notice Status of GMP Certification 2TPI QLF Achieved Public Notice Status of GMP Certification 3
... Q2 Revenue Up 46% to $4.83 Million; Net Income Up 59%... -- BEIJING, Aug. 16 /PRNewswire-Asia-FirstCall/ -- ... ... if (typeof(lpUnit)==,undefined,) var lpUnit=,PRN,; --> ... { var s = ,; var first_result; // Results are keyed by longUrl, so we need to ...
... Jiangbo Pharmaceuticals Announces the Commercial Launch of Felodipine Sustained Release Tablets -- LAIYANG, China, Aug. ... ... if (typeof(lpUnit)==,undefined,) var lpUnit=,PRN,; --> ... var shortURL = ""; BitlyCB.alertResponse = function(data) { var s = ,; var first_result; // ...
Cached Medicine Technology:Dehaier Medical Systems Q2 Revenue Up 46% to $4.83 Million; Net Income Up 59% to 1.14 Million; EPS 0.27 2Dehaier Medical Systems Q2 Revenue Up 46% to $4.83 Million; Net Income Up 59% to 1.14 Million; EPS 0.27 3Dehaier Medical Systems Q2 Revenue Up 46% to $4.83 Million; Net Income Up 59% to 1.14 Million; EPS 0.27 4Dehaier Medical Systems Q2 Revenue Up 46% to $4.83 Million; Net Income Up 59% to 1.14 Million; EPS 0.27 5Dehaier Medical Systems Q2 Revenue Up 46% to $4.83 Million; Net Income Up 59% to 1.14 Million; EPS 0.27 6Dehaier Medical Systems Q2 Revenue Up 46% to $4.83 Million; Net Income Up 59% to 1.14 Million; EPS 0.27 7Dehaier Medical Systems Q2 Revenue Up 46% to $4.83 Million; Net Income Up 59% to 1.14 Million; EPS 0.27 8Dehaier Medical Systems Q2 Revenue Up 46% to $4.83 Million; Net Income Up 59% to 1.14 Million; EPS 0.27 9Dehaier Medical Systems Q2 Revenue Up 46% to $4.83 Million; Net Income Up 59% to 1.14 Million; EPS 0.27 10Dehaier Medical Systems Q2 Revenue Up 46% to $4.83 Million; Net Income Up 59% to 1.14 Million; EPS 0.27 11Dehaier Medical Systems Q2 Revenue Up 46% to $4.83 Million; Net Income Up 59% to 1.14 Million; EPS 0.27 12Jiangbo Pharmaceuticals Announces the Commercial Launch of Felodipine Sustained Release Tablets 2Jiangbo Pharmaceuticals Announces the Commercial Launch of Felodipine Sustained Release Tablets 3Jiangbo Pharmaceuticals Announces the Commercial Launch of Felodipine Sustained Release Tablets 4Jiangbo Pharmaceuticals Announces the Commercial Launch of Felodipine Sustained Release Tablets 5Jiangbo Pharmaceuticals Announces the Commercial Launch of Felodipine Sustained Release Tablets 6Jiangbo Pharmaceuticals Announces the Commercial Launch of Felodipine Sustained Release Tablets 7
... creation of a vascular access, a correctly ... the utmost importance in many vascular procedures. ... seeking a high-precision tunneling instrument. The unique ... twisting or kinking for more accurate graft ...
... GORE-TEX Stretch Vascular Grafts have ... demanding vascular procedures. Recognized for exceptional ... the endorsement of renowned surgeons worldwide. ... dilatation and the spread of infection, ...
... vascular surgery, and the accompanying need for ... of graft be developed. Grafts must not ... also available in varying sizes and configurations ... has long been the prosthetic of choice ...
... newest vascular graft offering from W. L. ... surgical products for more than two decades, ... compression problems that can lead to ... of the benefits of a ring graft ...
Medicine Products: